{
  "pmcid": "5079604",
  "config": {
    "model": "gpt",
    "strategy": "zero-shot"
  },
  "usage": {
    "input": 14809,
    "output": 1094
  },
  "raw_text": "{\"extractions\":[{\"outcome\":\"Disposition index (DI)\",\"intervention\":\"subjects who remained in remission\",\"comparator\":\"patients with hyperglycemia relapse without significant changes in insulin sensitivity (Si)\",\"outcome_type\":\"continuous\",\"intervention_events\":null,\"intervention_group_size\":28,\"comparator_events\":null,\"comparator_group_size\":20,\"intervention_mean\":null,\"intervention_standard_deviation\":null,\"comparator_mean\":null,\"comparator_standard_deviation\":null},{\"outcome\":\"incremental area under the curve for insulin (AUCi)\",\"intervention\":\"subjects who remained in remission\",\"comparator\":\"patients with hyperglycemia relapse without significant changes in insulin sensitivity (Si)\",\"outcome_type\":\"continuous\",\"intervention_events\":null,\"intervention_group_size\":28,\"comparator_events\":null,\"comparator_group_size\":20,\"intervention_mean\":null,\"intervention_standard_deviation\":null,\"comparator_mean\":null,\"comparator_standard_deviation\":null},{\"outcome\":\"hyperglycemia relapse-free survival\",\"intervention\":\"metformin 1,000 mg daily\",\"comparator\":\"sitagliptin 100 mg daily\",\"outcome_type\":\"continuous\",\"intervention_events\":null,\"intervention_group_size\":17,\"comparator_events\":null,\"comparator_group_size\":16,\"intervention_mean\":null,\"intervention_standard_deviation\":null,\"comparator_mean\":null,\"comparator_standard_deviation\":null},{\"outcome\":\"Cox proportional hazards of failure-free survival\",\"intervention\":\"metformin 1,000 mg daily\",\"comparator\":\"sitagliptin 100 mg daily\",\"outcome_type\":\"continuous\",\"intervention_events\":null,\"intervention_group_size\":17,\"comparator_events\":null,\"comparator_group_size\":16,\"intervention_mean\":null,\"intervention_standard_deviation\":null,\"comparator_mean\":null,\"comparator_standard_deviation\":null},{\"outcome\":\"The restricted mean time to hyperglycemia relapse\",\"intervention\":\"metformin 1,000 mg daily, sitagliptin 100 mg daily\",\"comparator\":\"placebo\",\"outcome_type\":\"continuous\",\"intervention_events\":null,\"intervention_group_size\":33,\"comparator_events\":null,\"comparator_group_size\":15,\"intervention_mean\":480.0,\"intervention_standard_deviation\":null,\"comparator_mean\":305.0,\"comparator_standard_deviation\":null},{\"outcome\":\"Hyperglycemia relapse-free survival\",\"intervention\":\"metformin 1,000 mg daily, sitagliptin 100 mg daily\",\"comparator\":\"placebo\",\"outcome_type\":\"continuous\",\"intervention_events\":null,\"intervention_group_size\":33,\"comparator_events\":null,\"comparator_group_size\":15,\"intervention_mean\":null,\"intervention_standard_deviation\":null,\"comparator_mean\":null,\"comparator_standard_deviation\":null},{\"outcome\":\"The 2-year failure rate\",\"intervention\":\"metformin 1,000 mg daily, sitagliptin 100 mg daily\",\"comparator\":\"placebo\",\"outcome_type\":\"binary\",\"intervention_events\":null,\"intervention_group_size\":33,\"comparator_events\":null,\"comparator_group_size\":15,\"intervention_mean\":null,\"intervention_standard_deviation\":null,\"comparator_mean\":null,\"comparator_standard_deviation\":null},{\"outcome\":\"The probability of relapse\",\"intervention\":\"metformin 1,000 mg daily, sitagliptin 100 mg daily\",\"comparator\":\"placebo\",\"outcome_type\":\"binary\",\"intervention_events\":null,\"intervention_group_size\":33,\"comparator_events\":null,\"comparator_group_size\":15,\"intervention_mean\":null,\"intervention_standard_deviation\":null,\"comparator_mean\":null,\"comparator_standard_deviation\":null}]}",
  "extraction": [
    {
      "outcome": "Disposition index (DI)",
      "intervention": "subjects who remained in remission",
      "comparator": "patients with hyperglycemia relapse without significant changes in insulin sensitivity (Si)",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": 28,
      "comparator_events": null,
      "comparator_group_size": 20,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "5079604"
    },
    {
      "outcome": "incremental area under the curve for insulin (AUCi)",
      "intervention": "subjects who remained in remission",
      "comparator": "patients with hyperglycemia relapse without significant changes in insulin sensitivity (Si)",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": 28,
      "comparator_events": null,
      "comparator_group_size": 20,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "5079604"
    },
    {
      "outcome": "hyperglycemia relapse-free survival",
      "intervention": "metformin 1,000 mg daily",
      "comparator": "sitagliptin 100 mg daily",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": 17,
      "comparator_events": null,
      "comparator_group_size": 16,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "5079604"
    },
    {
      "outcome": "Cox proportional hazards of failure-free survival",
      "intervention": "metformin 1,000 mg daily",
      "comparator": "sitagliptin 100 mg daily",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": 17,
      "comparator_events": null,
      "comparator_group_size": 16,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "5079604"
    },
    {
      "outcome": "The restricted mean time to hyperglycemia relapse",
      "intervention": "metformin 1,000 mg daily, sitagliptin 100 mg daily",
      "comparator": "placebo",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": 33,
      "comparator_events": null,
      "comparator_group_size": 15,
      "intervention_mean": 480.0,
      "intervention_standard_deviation": null,
      "comparator_mean": 305.0,
      "comparator_standard_deviation": null,
      "pmcid": "5079604"
    },
    {
      "outcome": "Hyperglycemia relapse-free survival",
      "intervention": "metformin 1,000 mg daily, sitagliptin 100 mg daily",
      "comparator": "placebo",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": 33,
      "comparator_events": null,
      "comparator_group_size": 15,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "5079604"
    },
    {
      "outcome": "The 2-year failure rate",
      "intervention": "metformin 1,000 mg daily, sitagliptin 100 mg daily",
      "comparator": "placebo",
      "outcome_type": "binary",
      "intervention_events": null,
      "intervention_group_size": 33,
      "comparator_events": null,
      "comparator_group_size": 15,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "5079604"
    },
    {
      "outcome": "The probability of relapse",
      "intervention": "metformin 1,000 mg daily, sitagliptin 100 mg daily",
      "comparator": "placebo",
      "outcome_type": "binary",
      "intervention_events": null,
      "intervention_group_size": 33,
      "comparator_events": null,
      "comparator_group_size": 15,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "5079604"
    }
  ]
}